Patients must reside in Illinois
Behavior change is what makes the difference, and our latest randomized trial shows Noom members kept losing weight for a full year after the program ended
M.LombardiP.TillhonM.ScovassiA
Clinical trial data show that gastrointestinal adverse effectsincluding nausea, vomiting, diarrhea, and abdominal discomfortoccur in 20-50% of patients initiating GLP-1 therapy, with rates varying by specific agent and dose
Hector Perez, MD, lead bariatric surgeon at Renew Bariatrics and an advisor at Bariatric Reports, told Healthline that when it comes to weight loss, its too early to call survodutide a game-changer. [W]hile the reported weight loss number is impressive, we already have very strong performers in this category, he said